stockrow
Saturday 7 November 2026
Export SPTX’s income statement to Excel — free account
Seaport Therapeutics, Inc
SPTX Healthcare Biotechnology
- EPS
- +94.8%
- Free cash flow
- −43.8%
Quarter to September 2026, against a year earlier
21.18
0.79
+3.87%
Follow SPTX
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
27.82 | 17.46 |
Net Debt/EBITDA |
5.91 | 2.42 |
Debt/Assets |
0.11% | 0.00% |
Debt/Equity |
(0.01) | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.63 | 1.04 |
Capex/Depreciation |
(0.53) | 0.18 |
| 0.00% | 127.57% | |
| 0.00% | (26.52%) | |
ROIC |
0.00% | (324.62%) |
Return on Tangible Assets |
(15.67%) | (35.51%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(31.54) | (32.98) |
Cash per Share |
327.78 | 90.98 |
Shareholders Equity per Share |
(26.35) | 98.06 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(26.35) | 98.06 |
Free Cash Flow |
(29.74) | (78.30) |
Working Capital |
299.00 | 210.45 |
Capital Expenditures |
(0.11) | (0.36) |
Net Current Asset Value |
(30.47) | 207.00 |
| Other line items | ||
Quick Ratio |
27.72 | 16.90 |
Depreciation/Fixed assets |
0.89 | (4.91) |
Cash ROIC |
(10.45%) | (17.45%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(31.42) | (32.83) |
Capex per Share |
(0.12) | (0.15) |
Average Payables |
— | 3.37 |
Average Assets |
— | 282.39 |
Average Common Equity |
— | (58.70) |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026